Skip to content

Author

B. Barberio

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Meta-analysis Open access Oct 2026

Impact of body composition on clinical outcomes in patients with hepatocellular carcinoma: A systematic review and meta-analysis

Background: Abnormalities in body composition are common in patients with hepatocellular carcinoma (HCC); however, their impact across different treatment modalities remains poorly understood. We systematically reviewed the prognostic value of body composition in patients with HCC, stratified by curative, locoregional...

Elisa Pinto, B. Barberio, M. Gambato et al. · 0 citations
Review Open access Oct 2026

Dietary and Parenteral Nutritional Management of Short Bowel Syndrome with Intestinal Failure in Adults: A Narrative Review

A practical, physiology-anchored approach that maximises enteral autonomy and quality of life while preventing the metabolic, hepatic and catheter-related complications of long-term intravenous feeding is proposed.

B. Barberio, Beatrice Varotto, Matteo D'Angelo et al. · 0 citations
Review Open access Aug 2026

PD05.01. Unveiling the Risk of Esophageal Squamous Cell Carcinoma in Achalasia: End-Stage Disease Carries a Markedly Higher Prevalence and Incidence

Esophageal Cancer: Other Esophageal achalasia is a rare motility disorder associated with an increased risk of esophageal squamous cell carcinoma (ESCC), with reported prevalence ranging from 0.4% to 9.2%. The risk is particularly elevated in end-stage disease, characterized by longstanding stasis and sigm...

F. Forattini, R. Salvador, B. Barberio et al. · 0 citations
Open access Aug 2026

Circulating microRNAs as biomarkers of disease activity and treatment response in Crohn’s disease patients receiving infliximab or vedolizumab: a longitudinal cohort study

Serum miRNAs offer novel predictive and concurrent biomarker signals during biologic induction in Crohn’s disease, providing information complementary to faecal calprotectin.

Luisa Bertin, Lara Giraldi, Camilla Cavagna et al. · 0 citations
Open access Sep 2026

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Upadacitinib was effective and well-tolerated in AT-experienced Crohn's disease, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals.

B. Barberio, F. D'Amico, L. Laterza et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.